Casale Donn 4

What Happened Donn Casale, President of ARS Pharmaceuticals (SPRY), received a grant of 898,456 derivative shares (reported as an award/acquisition) on July 1, 2026. The reported acquisition price is $0.00, indicating a non-cash equity award (derivative security) rather than an open‑market purchase or sale.

Key Details

• Transaction date: July 1, 2026; Form 4 filed: July 2, 2026 (appears timely).
• Security: 898,456 derivative shares reported as an award/grant (transaction code A).
• Price: $0.00 (no cash paid at grant).
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: 25% of the shares subject to the award vest on June 1, 2027; the remainder vests monthly thereafter over three years.

Context This filing documents an equity award to an executive (a routine compensation event) rather than a market purchase or sale. Because it is a derivative award with staged vesting, the economic benefit is realized over time as vesting conditions are met; there was no immediate sale or cash exercise reported.